Phase 2b RCT in 190 adults with moderate-severe prurigo nodularis: vixarelimab 540, 360 and 120 mg cut worst itch at week 16 by 56.2%, 51.0% and 33.0% vs 14.5% with placebo. No serious treatment-related adverse events in the blinded period.
RCTn = 190
Ständer et al. Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial